Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record.

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial

Open access
Williams, Hywel C, Wojnarowska, Fenella, Kirtschig, Gudula, Mason, James, Godec, Thomas R, Schmidt, Enno, Chalmers, Joanne R, Childs, Margaret, Walton, Shernaz, Harman, Karen, Chapman, Anna, Whitham, Diane, Nunn, Andrew J, Adams, J, Akhras, V, Anstey, A, Barnard, C, Bell, H, Blackford, S, Bröcker, E, Carmichael, A, Coelho, R R, Craig, F, Davies, K, Ellis, R, English, J, Gläser, R, Groves, R, Günthert, C, Hampton, P J, Hepburn, N, Hügel, R, Hussain, K, Ingram, J, Layton, A M, Levell, N J, Lewis, V, Malhomme, H, Omerod, A, Patel, G, Rallan, R, Ravenscroft, J, Santander, H, Steinbrink, K, Sticherling, M, Thomas, C, Vatve, M, van Beek, N, Venning, V, Veysey, E, Wachsmuth, R, Wahie, S, Walker, B, Walsh, M, Wee, J, Westmoreland, M, Wong, G, Ferguson, Adam, Verpetinske, Indre, Duarte-Williamson, Emilia, Antony, Fiona, Bower, Chris, Gawkrodger, David, Taghipour, Kathy, Dunnill, M G S, Waters, Alex, Bottomley, Walter, Wright, Andrew, Sterling, Jane, Azam, Adzura, Gibbs, Sam, Luger, Thomas, Salvary, Ingrid, Lovell, Chris, Ilchyshyn, Andrew, Gibbon, Karen, Nik, Marinella, Charles-Holmes, Robert, Lavery, A Lloyd · 2017 · The Lancet

Abstract

BACKGROUND: Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids. METHODS: We did a pragmatic, multicentre, parallel-group randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0·5 mg/kg per day) using random permuted blocks of randomly varying size, and stratified by baseline severity (3-9, 10-30, and >30 blisters for mild, moderate, and severe disease, respectively). Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted during weeks 1-3. The non-inferiority primary effectiveness outcome was the proportion of participants with three or fewer blisters at 6 weeks. We assumed that doxycycline would be 25% less effective than corticosteroids with a 37% acceptable margin of non-inferiority. The primary safety outcome was the proportion with severe, life-threatening, or fatal (grade 3-5) treatment-related adverse events by 52 weeks. Analysis (modified intention to treat [mITT] for the superiority safety analysis and mITT and per protocol for non-inferiority effectiveness analysis) used a regression model adjusting for baseline disease severity, age, and Karnofsky score, with missing data imputed. The trial is registered at ISRCTN, number ISRCTN13704604. FINDINGS: Between March 1, 2009, and Oct 31, 2013, 132 patients were randomly assigned to doxycycline and 121 to prednisolone from 54 UK and seven German dermatology centres. Mean age was 77·7 years (SD 9·7) and 173 (68%) of 253 patients had moderate-to-severe baseline disease. For those starting doxycycline, 83 (74%) of 112 patients had three or fewer blisters at 6 weeks compared with 92 (91%) of 101 patients on prednisolone, an adjusted difference of 18·6% (90% CI 11·1-26·1) favouring prednisolone (upper limit of 90% CI, 26·1%, within the predefined 37% margin). Related severe, life-threatening, and fatal events at 52 weeks were 18% (22 of 121) for those starting doxycycline and 36% (41 of 113) for prednisolone (mITT), an adjusted difference of 19·0% (95% CI 7·9-30·1), p=0·001. INTERPRETATION: Starting patients on doxycycline is non-inferior to standard treatment with oral prednisolone for short-term blister control in bullous pemphigoid and significantly safer in the long-term. FUNDING: NIHR Health Technology Assessment Programme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)30560-3

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 226

Metadata

Authors
Williams, H. C., Wojnarowska, F., Kirtschig, G., Mason, J., Godec, T. R., Schmidt, E., Chalmers, J. R., Childs, M., Walton, S., Harman, K., Chapman, A., Whitham, D., Nunn, A. J., Adams, J., Akhras, V, Anstey, A., Barnard, C., Bell, H., Blackford, S., Bröcker, E., Carmichael, A., Coelho, R. R., Craig, F., Davies, K., Ellis, R., English, J., Gläser, R., Groves, R., Günthert, C., Hampton, P. J., Hepburn, N., Hügel, R., Hussain, K., Ingram, J., Layton, A. M., Levell, N. J., Lewis, V, Malhomme, H., Omerod, A., Patel, G., Rallan, R., Ravenscroft, J., Santander, H., Steinbrink, K., Sticherling, M., Thomas, C., Vatve, M., van Beek, N., Venning, V, Veysey, E., Wachsmuth, R., Wahie, S., Walker, B., Walsh, M., Wee, J., Westmoreland, M., Wong, G., Ferguson, A., Verpetinske, I., Duarte-Williamson, E., Antony, F., Bower, C., Gawkrodger, D., Taghipour, K., Dunnill, M. G. S., Waters, A., Bottomley, W., Wright, A., Sterling, J., Azam, A., Gibbs, S., Luger, T., Salvary, I., Lovell, C., Ilchyshyn, A., Gibbon, K., Nik, M., Charles-Holmes, R., & Lavery, A. L.
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-04
Volume
389
Issue
10079
Pages
1630-1638
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2575603189
Cited by
226
References
0
FWCI
17.43
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)30560-3
The paper
Williams, H. C., Wojnarowska, F., Kirtschig, G., Mason, J., Godec, T. R., Schmidt, E., Chalmers, J. R., Childs, M., Walton, S., Harman, K., Chapman, A., Whitham, D., Nunn, A. J., Adams, J., Akhras, V, Anstey, A., Barnard, C., Bell, H., Blackford, S., . . . Lavery, A. L. (2017). Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)30560-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.